transmembrane protein 217Genealiases: C6orf128 · dJ355M6.2
Q-omics provides the consensus-scored TMEM217 profile across patient tissues and cancer cell-line models. TMEM217 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, TMEM217 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, TMEM217 RNA expression shows 16,806 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight LUSC, HNSC, and KIRP as cancer lineages where TMEM217 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM217 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM217 survival associations across molecular data types. TMEM217 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM217 RNA expression–survival associations across cancer types. High TMEM217 expression shows unfavorable associations in LUSC, LGG and CHOL, but favorable associations in UVM, CESC and LUAD. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for TMEM217 RNA expression.
This table summarizes TMEM217 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM217. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM217 shows lower tumor expression in HNSC, KICH, BRCA and LUSC and higher tumor expression in THCA and LIHC. The HNSC box plot shows higher TMEM217 RNA expression in normal versus tumor tissue (log2 FC = −0.618, t-test p < 0.001).
This table shows molecular features associated with TMEM217 in patient tissues and cancer cell lines. In patient samples, TMEM217 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM217 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
